Intellia Therapeutics, Inc. NTLA

Here's how to play leading gene-editing stocks as Anthropic's AI tools make progress in the gene-editing space.

Anthropic says Claude identified a novel enzyme system with characteristics reminiscent of CRISPR

CRSP shares closed down 6% on Wednesday, while PRME and EDIT stocks declined 12% and 8%, respectively.

CRISPR Therapeutics owns the only approved gene therapy of its kind, yet the stock sits far below where Wall Street thinks it belongs. One analyst sees a path to gains that would embarrass the broader market, but the numbers tell a complicated story.

Intellia Therapeutics (NasdaqGM:NTLA) said the FDA accepted its Biologics License Application for lonvo-z for hereditary angioedema. The agency granted Priority Review status, positioning lonvo-z as a potential first in vivo CRISPR-based therapy in the U.S. The FDA does not plan to convene an advisory committee, with review supported by positive Phase 3 data and multiple global designations. The FDA's Priority Review of lonvo-z for hereditary angioedema is a key regulatory event to weigh...

The global in vivo gene editing market was valued at USD 3.4 billion in 2025 and is forecast to reach USD 22.6 billion by 2036, growing at a 16.8% CAGR from 2026. Growth is driven by CRISPR, base and prime editing, LNP and AAV delivery systems, precision medicine investment, and expanding clinical pipelines for genetic disorders, oncology, cardiovascular and neurological diseases. North America leads the market, while Asia-Pacific is expected to grow fastest. Key players include CRISPR Therapeut

Crispr stock, alongside other gene-editing equities, pulled a bullish move Thursday — bounding for a breakout from a cup-with-handle base.

Intellia Therapeutics, Inc. (NASDAQ:NTLA) entered a five-year senior secured credit facility with OrbiMed for up to $400 million and drew $75 million at closing. The remaining $325 million depends on milestones or further lender agreement. The facility bears interest at an annual rate equal to the greater of 3% or the one-month Secured Overnight Financing […]

The FDA accepted Intellia’s Biologics License Application for lonvoguran Ziclumeran for Hereditary Angioedema.

Intellia Therapeutics (NASDAQ:NTLA) shares rose 8% on Tuesday after the U. S.

FDA sets Prescription Drug User Fee Act (PDUFA) date of March 10, 2027Positions lonvo-z to be the world’s first in vivo CRISPR-based therapy and the only one-time HAE treatment, if approved CAMBRIDGE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the U.S. Food and Drug Administration (FDA) has accepted the Biol

Intellia Therapeutics (NTLA) stock is in focus after the company arranged a $400 million non dilutive senior secured term loan facility with OrbiMed to support lonvoguran ziclumeran, or lonvo z, development and launch plans. The financing news comes after a mixed period for Intellia Therapeutics. The share price is US$12.74, with a 30-day share price return of 16.13%, but the 3-year total shareholder return has declined 66.36% and the 5-year total shareholder return has declined 92.07%. Scan...

Intellia Therapeutics recently entered into a US$400 million non-dilutive senior secured term loan facility with OrbiMed, including a US$75 million initial draw and milestone-based tranches primarily linked to lonvoguran ziclumeran (lonvo-z) for hereditary angioedema, with full details to follow in an SEC Form 8-K filing. This financing structure, which ties most of the available capital to lonvo-z development milestones, highlights how central that program has become to Intellia’s funding...

CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on September 1, 2026, it awarded inducement grants to 41 new employees under Intellia’s 2024 Inducement Plan, as amended, as a material inducement to employment. The inducement grants consisted of time-based restricted stock units (“RSUs”) for an agg